Shanghai Kehua Bio-EngineeringLtd (002022) Stock Overview
Researches and develops, produces, and sells in vitro diagnostic reagents, medical testing equipment and other products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
002022 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shanghai Kehua Bio-Engineering Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.71 |
| 52 Week High | CN¥8.45 |
| 52 Week Low | CN¥4.88 |
| Beta | 0.44 |
| 1 Month Change | 1.67% |
| 3 Month Change | -1.47% |
| 1 Year Change | -2.61% |
| 3 Year Change | -47.62% |
| 5 Year Change | -63.41% |
| Change since IPO | -70.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002022 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.9% | -0.8% | -1.9% |
| 1Y | -2.6% | 4.7% | 18.4% |
Return vs Industry: 002022 underperformed the CN Biotechs industry which returned 4.7% over the past year.
Return vs Market: 002022 underperformed the CN Market which returned 18.4% over the past year.
Price Volatility
| 002022 volatility | |
|---|---|
| 002022 Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 9.3% |
| 10% least volatile stocks in CN Market | 3.2% |
Stable Share Price: 002022 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002022's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 2,033 | Ming Li | www.skhb.com |
Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic reagents, medical testing equipment and other products in China and internationally. It offers signature products, including immunoassay & clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management, and automated comprehensive solutions for nucleic acid blood screening; automatic modular and clinical chemistry analyzer; automatic chemiluminescence immunoassay analyzers; and CLIA reagents tests. The company also provides automatic microplate reader, microplate washer, and enzyme-linked immunoassay reagents; diagnostic kit for HIV and SARS-CoV-2 IgM/IgG antibody; and fully automated nucleic acid blood screening laboratory and molecular diagnostics solutions.
Shanghai Kehua Bio-Engineering Co.,Ltd Fundamentals Summary
| 002022 fundamental statistics | |
|---|---|
| Market cap | CN¥3.36b |
| Earnings (TTM) | -CN¥750.99m |
| Revenue (TTM) | CN¥1.60b |
Is 002022 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002022 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.60b |
| Cost of Revenue | CN¥1.20b |
| Gross Profit | CN¥397.87m |
| Other Expenses | CN¥1.15b |
| Earnings | -CN¥750.99m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.50 |
| Gross Margin | 24.86% |
| Net Profit Margin | -46.93% |
| Debt/Equity Ratio | 17.6% |
How did 002022 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/27 03:04 |
| End of Day Share Price | 2025/11/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Kehua Bio-Engineering Co.,Ltd is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Zou | China International Capital Corporation Limited |
| Andy Liu | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Jie Yao | Citic Securities Co., Ltd. |